Search the Newsreel

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

UTStarcom (NASDAQ: UTSI) revenue falls 26% as net loss deepens in 1H 2026

UTStarcom Holdings Corp. (NASDAQ: UTSI) reported a 26.1% drop in revenue to $3.4 million and a widened net loss of $5.1 million for the first half of 2026, compared to the same period in 2025. The company experienced a gross loss of $0.5 million, …

Marcus & Millichap (MMI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 10:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Hessam NadjiChief Financial Officer - Steve DeGennaro TAKEAWAYS Total Revenue -- $203 million, an 18% increase compared to $172 million in the …

AksharChem (India) Ltd Locks at Upper Circuit With 4.35% Gain — Buyers Queue, Sellers Absent

Arch Capital Group Ltd. $ACGL Stock Holdings Trimmed by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in Arch Capital Group Ltd. by 26.9% in the second quarter, selling 31,494 shares and retaining 85,444 shares valued at $8.3 million. Despite this trimming, Arch Capital exceeded quarterly expectations with strong EPS and revenue, and institutional investors …

Quantinno Capital Management LP Acquires 40,335 Shares of Marcus & Millichap, Inc. $MMI

Quantinno Capital Management LP significantly increased its stake in Marcus & Millichap (NYSE:MMI) by 348.4% in the first quarter, acquiring an additional 40,335 shares to bring its total holding to 51,913 shares. The real estate investment trust reported strong financial results, beating analysts' consensus …

Digimarc Corporation $DMRC Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Digimarc Corporation ($DMRC) by 179.6% in the first quarter, now owning 293,249 shares valued at approximately $1.44 million. Other institutional investors also adjusted their positions, with institutional ownership collectively reaching 66.85%. Despite the company beating …

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …

Burney Co. Sells 30,723 Shares of Lam Research Corporation $LRCX

Burney Co. reduced its stake in Lam Research Corporation by 13.1%, selling 30,723 shares but still holding 204,176 shares valued at $88.5 million. Institutional investors collectively own a significant 84.61% of the company, and analysts maintain a "Moderate Buy" rating with an average price …

Fisher Funds Management LTD Has $13.57 Million Stake in Lam Research Corporation $LRCX

Fisher Funds Management LTD significantly reduced its stake in Lam Research Corporation by 41.4% in the second quarter, selling over 22,000 shares but still holding shares valued at $13.57 million. Despite strong quarterly financial results from Lam Research and positive analyst ratings, company insiders …

Archidply Decor Q1 Results: Net Loss Widens 73% YoY To ₹24.95 Lakh

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

United Parcel Service, Inc.: Konsensus der Analysten und Kursziel | 929198 | US9113121068

Archer Daniels Midland (ADM) Earnings Date and Reports 2026 $ADM

FactSet Research Systems (FDS) Earnings Date and Reports 2026 $FDS

What's Going On With Lam Research Stock Thursday?

Lam Research stock traded mostly flat on Thursday, consolidating after a strong 12-month run, with investors watching key technical support levels. The company is also expanding its semiconductor workforce development initiatives and its operations in Singapore. Despite a premium valuation and mixed near-term technical …

Integrated Research (ASX:IRI)flags 17 per cent revenue slide

Arch Insurance Intl. appoints James Mecham as Deputy CUO for Long Tail Lines

Arch Insurance International has appointed James Mecham as Deputy Chief Underwriting Officer (CUO) for Long Tail Lines, effective immediately. Mecham will support the underwriting strategy for long tail portfolios across various business units and will also serve as Head of General Casualty. This appointment …

Lam Research Plans To Invest Over $3 Bln To Expand Research, Development Lab Network In AI Era

(RTTNews) - Lam Research Corporation (LRCX), a semiconductor manufacturing equipment and services provider, said that it intends to invest more than $3 billion over the next five years to expand its global research and development lab network. This investment will increase the company's experiment …

Arcos Dorados Holdings Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:ARCO) 2026-08-14

This article first appeared on GuruFocus. Total Revenue: Reached $1.3 billion, the highest ever quarterly revenue, up more than 14% versus the prior year quarter. System-wide Comparable Sales: Grew 15.3%, driven by a higher average check and the best guest volume performance of the …

What's Going On With High Arctic Energy Services Inc. Stock Thursday?

Why Lam Research (LRCX) Is Up 10.2% After $3 Billion Global R&D Lab Expansion Plan

In August 2026, Lam Research announced plans to invest more than US$3.00 billion over five years to expand its global R&D lab network, aiming to lift experiment capacity by over 50% and compress product development cycles for semiconductor customers across the US, Asia, and …

Barclays PLC (TAVI) discloses 15,654-share stake in Tavia Acquisition Corp

Barclays PLC has disclosed a beneficial ownership of 15,654 shares in Tavia Acquisition Corp (TAVI), representing 0.17% of the common stock. This filing, a SCHEDULE 13G/A, indicates that Barclays PLC holds sole voting and dispositive power over these shares, categorizing the stake as less …

Archrock (AROC) Could Be 21% Undervalued On Strong Q2 Results And Higher Guidance

Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …

Marcus & Millichap arranges $3.9 million sale of 56,000 s/f 470 Pine St.

Marcus & Millichap successfully brokered the sale of 470 Pine St., a 56,000 square foot multi-tenant building in downtown Manchester, NH, for $3.9 million. The property, originally built in 1924 and converted from a mill to a school, is fully occupied by three educational …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

Arcadia Biosciences earnings missed by $1.53, revenue fell short of estimates

Arcturus (ARCT) Q2 2026 Earnings Call Transcript

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …

Digimarc outlines go-to-market rebuild as Secure Gift Card pipeline grows over 30x to more than 31 retailers

Earnings Call Insights: Digimarc (DMRC) Q2 2026 MANAGEMENT VIEW * CEO Paul Carreiro framed the quarter around execution changes, saying Digimarc is “held back by commercial execution gap that is entirely fixable” and that “what was missing was leadership focus, structure and accountability to …

Barclays PLC (NHIC) trims Newhold Investment Corp II-A stake to 4.13% of shares

Barclays PLC has reported a reduction in its beneficial ownership of Newhold Investment Corp II-A common stock, now holding 4.13% of the class. This amounts to 863,817 shares, with the majority having sole voting and dispositive power. The filing indicates that Barclays' stake is …

Barclays PLC (PEN) discloses 2.34M-share beneficial stake in Penumbra Inc

Barclays PLC has reported a beneficial ownership of 2,342,118 shares of Penumbra Inc (PEN) common stock, representing 5.95% of the class as of June 30, 2026. The filing, a Schedule 13G, indicates that Barclays holds sole voting and dispositive power over 2,340,999 shares and …

Barclays PLC discloses 1.23M Axiom Intelligence (AXIN) shares on Schedule 13G

Barclays PLC has reported a beneficial ownership of 1,231,531 shares of Axiom Intelligence (AXIN) Class A common stock, representing a 5.97% stake. The filing indicates Barclays PLC has sole voting and dispositive power over 1,201,531 shares, and shared power over an additional 30,000 shares. …

Digimarc Reports Second Quarter 2026 Financial Results

Digimarc Corporation reported its second-quarter 2026 financial results, with total revenue decreasing to $7.4 million from $8.0 million in Q2 2025, primarily due to lower subscription revenue following contract expirations. Despite a net loss increase to $12.1 million, the company's CEO, Paul Carreiro, expressed …